Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For medical device manufacturers located outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a mandatory step for placing devices on the market in Great Britain (England, Wales, a...
When budgeting for compliance with EU cosmetic regulations, particularly with new ingredient restrictions and updated requirements taking effect, manufacturers often focus on the cost of appointing a ...
When a medical device is designated as Class II, it must comply with both General Controls and Special Controls to ensure a reasonable assurance of safety and effectiveness. While the Code of Federal ...
As the medical device industry prepares for anticipated updates to key biocompatibility standards, such as revisions to the ISO 10993 series, what is a comprehensive framework for updating a Biologica...
For medical device manufacturers based outside the United Kingdom, what are the key requirements and strategic considerations for appointing or re-evaluating their UK Responsible Person (UKRP) in ligh...
Given the significant legal responsibilities and shared liability placed upon the EU Authorised Representative (AR) under the Medical Device Regulation (MDR), how should a non-EU medical device manufa...
When developing a novel pharmacogenetic or drug-metabolizing enzyme genotyping system, how should sponsors effectively integrate device-specific special controls with the broader requirements outlined...
When a non-EU medical device manufacturer is selecting an EU Authorized Representative (AR) under the Medical Device Regulation (EU) 2017/745 (MDR), what specific, in-depth questions should be asked t...
For a non-UK manufacturer of a medical device, such as a Class IIa wearable biosensor or a complex Software as a Medical Device (SaMD), what comprehensive framework should be used to select a UK Respo...
Given the evolving EU cosmetic regulatory landscape, with significant updates anticipated around 2026, the selection of a qualified EU Responsible Person (RP) has become a critical strategic decision ...
For US-based manufacturers of connected medical devices, such as Software as a Medical Device (SaMD), navigating global regulations presents significant challenges. While preparing for a US premarket ...
As non-EU manufacturers navigate the complexities of placing products on the European market, understanding the distinct roles of various "representatives" is critical. The term "EU Authorized Represe...
When foreign cosmetic companies seek a U.S. Agent to comply with the Modernization of Cosmetics Regulation Act (MoCRA), understanding the associated costs is a primary concern. While specific fees are...
Given the dynamic nature of EU cosmetics regulations, how should a non-EU brand strategically evaluate and select a European Responsible Person (RP) to ensure robust compliance ahead of anticipated 20...
For non-EU based medical device manufacturers, especially those with Software as a Medical Device (SaMD) or connected devices processing health data from EU residents, understanding the evolving oblig...
For non-EU medical device manufacturers, how can they strategically select an EU Authorized Representative (AR) in full alignment with the heightened responsibilities outlined in Regulation (EU) 2017/...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), what are the specific responsibilities, qualifications, and practical liabilities for an FDA U.S. Agent representing a...
When a medical device manufacturer, particularly a small or medium-sized enterprise, decides to outsource the role of the Person Responsible for Regulatory Compliance (PRRC) under European regulations...
For manufacturers of connected medical devices, such as a wearable cardiac monitor or an integrated continuous glucose monitoring system (iCGM), what are the key components of a robust cybersecurity r...
With the EU's Carbon Border Adjustment Mechanism (CBAM) set to introduce significant new reporting obligations for importers, how should non-EU medical device manufacturers re-evaluate the role and re...